A new Netflix documentary called “Have a Good Trip: Adventures in Psychedelics” premiered on Netflix on May 11 this year and it is generating quite a buzz because of the topic it explores. In this documentary, several stars share their experiences of taking psychedelic drugs. Actors reenact those experiences being described by the celebrities, and experts delve into the science of why and what psychedelics can offer the medical community.
The lineup of celebrities who feature in the documentary is quite impressive. They include Ben Stiller, Sarah Silverman, and Natasha Lyonne. Even stars who have passed on, such as Carrie Fisher and Anthony Bourdain, have their psychedelic experiences reenacted by actors.
The main psychedelic substances that these actors confess to having tried out are LSD and magic mushrooms. The rapper A$AP Rocky reveals that when he consumed LSD, a rainbow shot out of his privates, while the musician Sting says that the grass around him started having a conversation with him! Rosie Perez says that when she consumed psychedelics, she felt that her entire body became one with the mattress on which she was lying. All these wild moments are brought to life by vivid renditions of those scenes.
The documentary isn’t all about telling the wild stories of celebrities. Researchers bring a touch of seriousness to this whole “psychedelic trip thing” by explaining the science of how those substances work, as well as their potential to treat a variety of mental health disorders, such as addiction, anxiety and depression.
For example, a researcher explains in one of the scenes that psychedelics alter the way information is transmitted through the brain. A very powerful image of a series of highways is used to illustrate this change. Viewers are invited to imagine how traffic moves along different highways, with some choking up while others have very light traffic.
The same can happen in the brain, with some pathways being overused while others hardly have any traffic on them. When you consume psilocybin or another psychedelic, some traffic is moved away from the overused mental highways to those that aren’t getting as much action.
For a person who suffers from depression, PTSD or other such conditions, shifting traffic from their overloaded pathways of negative emotions or memories can be life-transforming, and that is how psychedelics can help.
There is plenty of research still being done, and the studies available so far indicate that a huge transformation in the way mental health care is delivered will be ushered in once psychedelics are fully understood and exploited. That potential could explain why Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) and others in this emerging industry are putting a lot of resources into developing a range of products for different populations.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news on the latest developments in therapeutic psychedelics, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW has secured a unique strategic position in the therapeutic psychedelics market, and our team of journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the therapeutic psychedelics industry.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
